Author

Pilar Garrido

Hospital Universitario Ram

Biography

Pilar Garrido is Associate Professor of Medical Oncology at Universidad de Alcalá (Madrid, Spain) and serves as Head of the Thoracic Tumours Section in the Medical Oncology Department at the University Hospital Ramón y Cajal in Madrid, Spain. 
Title
Cited by
Year
Amivantamab in EGFR exon 20 insertion–mutated non–small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study
K Park, EB Haura, NB Leighl, P Mitchell, CA Shu, N Girard, S Viteri, ...Journal of Clinical Oncology 39 (30), 3391-3402, 2021202
289
2021
Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial
V Subbiah, PA Cassier, S Siena, E Garralda, L Paz-Ares, P Garrido, ...Nature medicine 28 (8), 1640-1645, 2022202
51
2022
The impact of COVID-19 on oncology professionals—one year on: lessons learned from the ESMO Resilience Task Force survey series
KHJ Lim, K Murali, E Thorne, K Punie, K Kamposioras, C Oing, ...ESMO open 7 (1), 100374, 2022202
23
2022
Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: findings from …
N Girard, J Bar, P Garrido, MC Garassino, F McDonald, F Mornex, ...Journal of Thoracic Oncology 18 (2), 181-193, 202
23
2023
ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non–Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges
LQM Chow, F Barlesi, EM Bertino, MJ Van Den Bent, HA Wakelee, ...Clinical Cancer Research 28 (12), 2506-2516, 2022202
19
2022
Targeting KRAS in non-small cell lung cancer
E Corral de la Fuente, ME Olmedo Garcia, A Gomez Rueda, Y Lage, ...Frontiers in Oncology 11, 792635, 2022202
15
2022
Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumors.
MJ Krzakowski, S Lu, S Cousin, EF Smit, C Springfeld, K Goto, P Garrido, ...Journal of Clinical Oncology 40 (16_suppl), 3099-3099, 2022202
13
2022
Implementing lung cancer screening in Europe: taking a systems approach
S Wait, A Alvarez-Rosete, T Osama, D Bancroft, R Cornelissen, A Marušić, ...JTO Clinical and Research Reports 3 (5), 0329, 2022202
10
2022
A definitive prognostication system for patients with thoracic malignancies diagnosed with Coronavirus disease 2019: An update from the TERAVOLT registry
JG Whisenant, J Baena, A Cortellini, LC Huang, GL Russo, L Porcu, ...Journal of Thoracic Oncology 17 (5), 661-674, 2022202
10
2022
Female leadership in oncology—has progress stalled? Data from the ESMO W4O authorship and monitoring studies
AS Berghoff, C Sessa, JCH Yang, Z Tsourti, J Tsang, J Tabernero, ...ESMO open 6 (6), 100281, 2021202
9
2021
Expert opinion on NSCLC small specimen biomarker testing—Part 1: Tissue collection and management
F Penault-Llorca, KM Kerr, P Garrido, E Thunnissen, E Dequeker, ...Virchows Archiv 481 (3), 335-350, 2022202
9
2022
Expert opinion on NSCLC small specimen biomarker testing—Part 2: Analysis, reporting, and quality assessment
F Penault-Llorca, KM Kerr, P Garrido, E Thunnissen, E Dequeker, ...Virchows Archiv 41 (3), 351-366, 2022202
8
2022
Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer …
M Provencio, J Terrasa, P Garrido, RG Campelo, F Aparisi, P Diz, ...BMC cancer 21 (1), 1-12, 2021202
8
2021
Efficacy of brigatinib in patients with advanced ALK-positive NSCLC who progressed on alectinib or ceritinib: ALK in lung cancer trial of brigAtinib-2 (ALTA-2)
SHI Ou, M Nishio, MJ Ahn, T Mok, F Barlesi, C Zhou, E Felip, F de Marinis, ...Journal of Thoracic Oncology 17 (12), 1404-1414, 2022202
6
2022
New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of …
D Isla, MD Lozano, L Paz-Ares, C Salas, J de Castro, E Conde, E Felip, ...Clinical and Translational Oncology 2 (), 122-1267, 2023202
5
2023
Overcoming immunosuppression and pro-tumor inflammation in lung cancer with combined IL-1β and PD-1 inhibition
JM Lee, M Tsuboi, ES Kim, TSK Mok, P GarridoFuture Oncology 18 (27), 3085-3100, 2022202
4
2022
La Formación Médica Continuada de las Sociedades Científicas en España: análisis de la situación actual y propuestas de futuro
J García-Alegría, B Abarca Buján, A Íñiguez Romo, P Garrido LópezMedicina Clínica 159 (1), 7-52, 2022202
4
2022
Future care for long-term cancer survivors: towards a new model
M Provencio, N Romero, J Tabernero, R Vera, DV Baz, A Arraiza, ...Clinical and Translational Oncology, 1-13, 2022202
4
2022
Efficacy of brigatinib in patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer who progressed on alectinib or ceritinib: ALTA-2 study
OSH Ignatius, M Nishio, MJ Ahn, T Mok, F Barlesi, C Zhou, E Felip, ...JOURNAL OF THORACIC ONCOLOGY, 1-10, 2022202
3
2022
Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey
H Linardou, AA Adjei, J Bajpai, S Banerjee, AS Berghoff, CC Mathias, ...ESMO open 8 (2), 100781, 20220
3
2023

Referred From: https://scholar.google.com/citations?user=1DZncWkAAAAJ&hl=es

Cited by
Citations 14356
h-index 40
i10-index 111
Recommended Journals
Open Access Journals